Psyence Biomedical Ltd

Psyence Biomedical announced a share swap under which it will acquire 2,900 shares of Psyence Labs valued at $5 million (USD $1,724 per share) and issue 1,146,159 of its own common shares in exchange (based on a 30‑day VWAP of $4.36). The transaction involves no cash consideration; after the issuance Psyence Labs would hold approximately 49.98% of Psyence Biomedical’s outstanding common shares. Closing is expected on or about February 25, 2026, and is subject to customary conditions, including evidence of fair market value and the absence of any material adverse events. An independent special committee reviewed and approved the agreement; the investment is intended to strengthen the companies’ strategic alignment and their supply and licensing relationships. » Más en de.investing.com

Psyence Biomedical’s stock fell about 5.7% after the company reached a settlement with shareholder KAOS Capital to resolve a direct lawsuit. Psyence will pay $1.5 million and waive court cost recovery of CAD 75,000; KAOS will also sell its common shares at $5 per share to a third party designated by the company. Both parties mutually waive claims and KAOS withdraws the allegations; Psyence stresses the settlement is not an admission of liability and will be funded from existing cash. » Más en de.investing.com

Psyence Biomedical will implement a postponed 1:6.25 share consolidation on 2 February 2026; outstanding common shares will fall from 6,388,604 to about 1,022,177. The stock trades at $0.77, far below the 52-week high of $14.74; the company recorded a price decline of about 92.8% over the past year. Warrants and other equity instruments will be adjusted proportionally, and fractional shares will be rounded. This is the second consolidation in less than a year after the 1:7.97 split in May 2025; the company faces significant financial difficulties and was not profitable in the last twelve months. » Más en de.investing.com